The study found a significant discrepancy between recommended adjuvant chemotherapy and actual use, with younger women more likely to receive treatment. Overall, only 29% of women received chemotherapy, highlighting the need for re-evaluation of current NIH guidelines.
A study on breast cancer treatment found that many women do not receive adjuvant chemotherapy as recommended, with age being a significant factor. In contrast, women with known heart disease are at high risk of future heart events but often lack preventive treatments, highlighting the need for better care coordination.
Two trials found that adjuvant chemotherapy improved recurrence-free survival by 8-11% and overall survival by 5-9%, primarily benefiting patients with unrecognized residual disease. These findings suggest that adjuvant chemotherapy may be most effective in patients with non-optimal surgical staging.
A novel treatment approach combining surgery and intraperitoneal hyperthermic chemotherapy (IPHC) has shown significant promise in improving survival rates for patients with peritoneal carcinomatosis. The study found that selected patients may benefit from improved quality of life and extended survival.
Researchers have discovered that combining Avastin with chemotherapy provides superior treatment for advanced colorectal cancer, increasing median survival by 8.3 months and response rates. The study's findings suggest a more effective and less toxic option for patients with this devastating form of cancer.
Researchers at Dana-Farber Cancer Institute found that combination therapy of cytarabine, daunorubicin, and Mylotarg achieved complete remission in 83% of evaluable participants. The treatment was well-tolerated, with no significant increase in side effects.
A phase II clinical trial shows the oral combination of thalidomide and dexamethasone reduces tumor size by 50% or more in 64% of newly diagnosed multiple myeloma patients. This treatment alternative offers a promising solution to chemotherapy's side effects, including nausea, vomiting, and hair loss.
A new trial shows that high-dose chemotherapy has no significant benefits for women with severe breast cancer. However, molecularly targeted drugs in combination with chemotherapy show promising results.
A new phase III multi-national European trial involving 618 patients with advanced non small-cell lung cancer found that cisplatin and paclitaxel improved survival rates compared to carboplatin and paclitaxel. The study suggests that cisplatin-based chemotherapy remains the preferred standard treatment for lung cancer in Europe.
A randomized trial found that adding chemotherapy to tamoxifen significantly increases disease-free and overall survival rates for postmenopausal women with lymph node-negative, ER-negative breast cancer. In contrast, no survival benefit was observed for those with ER-positive tumors.
Patients with ER-negative tumors who received chemotherapy had a 15% increase in disease-free survival and 89% overall survival rate. In contrast, those with ER-positive tumors did not show additional survival benefits from chemotherapy. The study suggests tailoring cancer treatments to patient characteristics.
A study published in Journal of Clinical Oncology found that self-taught stress management techniques, such as progressive muscle relaxation and guided imagery, can significantly improve the quality of life for cancer patients undergoing chemotherapy. These techniques were more effective than traditional methods when learned independen...
Kytril was found to be significantly more effective than dolasetron in controlling acute chemotherapy-induced nausea and vomiting. The study, led by Dr. Marianne Tan, showed that 69.2% of patients treated with Kytril experienced total control of nausea and vomiting, compared to 23.1% for dolasetron.
A new clinical trial at NCCAM investigates the effectiveness of electroacupuncture in managing delayed chemotherapy-induced nausea, which often proves difficult to treat with medications. The study aims to provide an alternative approach to alleviate this condition and its associated side effects, such as stress.
Researchers developed a test to predict which patients with locally advanced breast cancer are likely to respond to chemotherapy, and found it was accurate 100% of the time. The test used radiotracer uptake and washout rates to identify patients who would benefit from specific drugs to boost their response.
Researchers evaluated 407 patients who had surgery to remove their cancer and were at high risk for recurrence. The study found no significant difference between radiation alone and chemotherapy plus radiation in reducing cancer recurrence or improving overall survival rates.
A recent study by the Southwest Oncology Group found that long-term treatment with prednisone after initial chemotherapy response significantly prolonged patient survival and delayed disease progression in those with multiple myeloma. Patients receiving higher doses of prednisone lived up to 37 months longer than those on lower doses.
Systematic review and meta-analysis of 12 randomised trials shows a 6% increase in one-year survival for patients receiving chemotherapy with radiotherapy compared to those receiving radiotherapy alone. Patients also experience a two-month improvement in average survival time.
Researchers at Massachusetts General Hospital found that a certain chemotherapy drug combination can increase the risk of lung inflammation in breast cancer patients. The study suggests doctors use extra caution when administering radiation therapy with paclitaxel, as it may lead to radiation pneumonitis in up to 14.6% of patients.
A new study published in New England Journal of Medicine found that age alone should not determine whether an older patient is offered chemotherapy after surgery for treatment of stage II and III colon cancer. The study showed a significant reduction in death risk and improved survival rates among patients over 70 with the disease.
Research studies found that low MBL concentrations are associated with prolonged fever and infection in cancer patients undergoing chemotherapy. MBL infusions may represent a new therapeutic approach to reduce illness and death for these patients.
A recent trial found that WHO short-course chemotherapy was as effective as traditional Russian treatments in curing patients with tuberculosis. However, the results highlight the challenges of implementing changes in a healthcare system with entrenched cultural and structural barriers.
A statistical analysis of 47 randomized trials involving 18,000 women found that chemotherapy improves survival time adjusted for quality of life for both younger and older women. Younger women treated with chemotherapy gained an average of 10.3 months of relapse-free survival within 10 years.
Researchers at Johns Hopkins Oncology Center discovered a genetic alteration in tumor samples that predicts patient response to chemotherapy. The methyl-guanine-DNA methyltransferase (MGMT) gene was found to be altered in 19 patients, resulting in better responses to chemotherapy and increased long-term survival.
A recent study conducted at Indiana University Medical Center found that high-dose chemotherapy followed by stem-cell transplantation can achieve a durable remission in approximately 50% of patients with recurrent testicular cancer. The overall cure rate for these patients is now estimated to be around 85 percent.
Researchers found that concurrent chemotherapy and daily chest radiation can help lung cancer patients live longer, with an average survival of 17 months. In contrast, sequential treatment resulted in an average survival of 14.6 months.
Researchers found that combretastatin A-4 prodrug significantly enhances the effectiveness of standard chemotherapy agents in laboratory animals. Combining the drug with chemotherapy resulted in a 10 to 500 times increase in tumor cell death, compared to using chemotherapy alone.
Researchers present study showing implanted chemotherapy pump significantly increases survival rates for patients with liver metastases from colorectal cancer. The pump distributes chemotherapy directly to the liver, resulting in reduced recurrence and improved outcomes.
A study published in Neurosurgery found that 42% of patients survived five years or more after receiving enhanced chemotherapy through blood-brain barrier disruption. The treatment also showed no cognitive loss or impairment in 36 patients, contrary to previous studies.
Researchers found that patients who previously received hormone therapy with tamoxifen, had no prior chemotherapy, and had limited metastases were more likely to live longer after high-dose chemotherapy with transplant. This study suggests that closely monitoring high-risk patients can improve treatment outcomes.
Researchers at the University of Iowa report improved survival rates for women with stage IV breast cancer using a four-drug, high-dose chemotherapy treatment followed by a bone marrow transplant. The study found an overall survival rate of 38 percent, compared to projected rates of 32-30 percent in other studies.
Researchers developed CMA-676, an antibody-drug conjugate targeting AML cells while sparing normal blood cells. The treatment produces mild side effects and induces remission comparable to standard chemotherapy regimens.
Researchers at Penn discovered that chemoembolization doubles the survival time of adult patients with colon cancer that has spread to the liver. The procedure, which delivers chemotherapy directly to tumor cells, outperforms systemic chemotherapy in managing metastasized disease.
A new experimental compound, CMA-676, demonstrates promising efficacy in treating acute myelogenous leukemia (AML) with an antibody-targeted chemotherapy approach. The treatment shows a remission rate of approximately 40% comparable to standard combination chemotherapy regimens.
The study aims to scientifically evaluate the benefits of a Chinese herbal formula in alleviating multiple side effects of chemotherapy in early-stage breast cancer patients. Participants will receive either the herbal formula or a placebo, with their progress monitored over 180 days.
Researchers discovered specific genetic changes that indicate whether chemotherapy is effective in treating patients with anaplastic oligodendrogliomas. The discovery allows for immediate determination of chemotherapy response at diagnosis, offering improved treatment options for patients.
A large-scale randomized study found that chemotherapy improves long-term survival for women under 50 and those in their 50s and 60s, even if the cancer has not spread. The treatment also showed benefits for women without evidence of disease spread.
Duke researchers have identified a lung condition in breast cancer patients that can limit therapy choices if not treated promptly. The disorder, DPTS, is successfully treated with inexpensive corticosteroids, improving pulmonary function by 17%.
Researchers at the University of Pennsylvania School of Medicine have identified a novel death-receptor gene called KILLER/DR5 that responds to chemotherapy and radiation by killing cancer cells. The discovery provides new insights into how cancer cells are killed after treatment, with potential implications for improving cancer therapy.
Researchers at University at Buffalo and Roswell Park Cancer Institute found no link between chemotherapy use and cancer risk in children's offspring. The study analyzed health records of 153 children born to 91 chemotherapy patients, showing none developed cancer.